SEC Form 4 · accession 0001209191-15-054223
China Biologic Products, Inc. · CBPO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Hui Li
Director
Period of report
Jun 15, 2015
Accepted (ET)
Jun 17, 2015 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1,F2,F3,F4 | Jun 15, 2015 | S | 2,645,000 | $100.275 | D | 8,344,200 | I | See footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of common stock, $0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were sold pursuant to that certain underwriting agreement dated June 10, 2015 (the "Underwriting Agreement"), entered into by and among China Biologic Products, Inc. (the "Issuer"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X," together with WP X, the "Funds") and Morgan Stanley & Co. International plc, Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC as representatives to the underwriters named in the Underwriting Agreement (collectively, the "Underwriters"). At the closing of the transaction contemplated under the Underwriting Agreement on June 15, 2015, the Funds sold an aggregate of 2,645,000 shares of Common Stock to the Underwriters for a purchase price of $265,227,375.00, or $100.275 per share.
- F2The 8,344,200 shares of the Common Stock of the Issuer are held by WP X Biologics LLC, a Delaware limited liability company ("WP X B"), WP X and holder of 96.9% of the equity interest in WP X B, and WPP X and holder of 3.1% of the equity interest in WP X B. Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP"), is the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), is the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WP X GP, Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), is the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"),
- F3(Continued from Footnote 2) is the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company, is the managing member of WPP GP LLC, and Warburg Pincus LLC, a New York limited liability company ("WP LLC"), manages each of the Funds.
- F4Mr. Li is a Managing Director and Member of WP LLC. As such, Mr. Li may be deemed to have an indirect pecuniary interest (within the meaning of Rule 16a-1 under the Securities and Exchange Act of 1934, as amended (the "Exchange Act")) in an indeterminate portion of the securities reported as beneficially owned by the Funds and WP X B. Mr. Li disclaims beneficial ownership of such securities, except to the extent of any direct pecuniary interest therein. Mr. Li does not directly own any shares of Common Stock of the Issuer.
Remarks
* This Form 4 shall not be deemed an admission that the Reporting Person or any other person referred to herein is a beneficial owner of the shares of Common Stock held by the Funds and WP X B for purposes of Section 16 of the Exchange Act or for any other purpose.